1.24
+0.05(+4.20%)
Currency In USD
| Previous Close | 1.19 |
| Open | 1.21 |
| Day High | 1.24 |
| Day Low | 1.16 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.75 |
| Volume | 509,611 |
| Average Volume | 216,872 |
| Market Cap | 45.44M |
| PE | -3.26 |
| EPS | -0.38 |
| Moving Average 50 Days | 1.18 |
| Moving Average 200 Days | 1.17 |
| Change | 0.05 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $170.8 as of September 07, 2025 at a share price of $1.24. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $504.07 as of September 07, 2025 at a share price of $1.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
GlobeNewswire Inc.
Aug 06, 2025 12:30 PM GMT
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of Ren
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
GlobeNewswire Inc.
Dec 11, 2024 1:00 PM GMT
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appoin
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
Shaun Bagai to discuss RenovoRx’s 2024 achievements and 2025 outlook, including important milestones for commercialization of RenovoCath and Phase III TIGeR-PaC trialLOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or